Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Author's Takes
  • Reviews
    • View all reviews ...
    • Aging (Upcoming)
    • Next-Generation Sequencing in Medicine (Jun 2022)
    • New Therapeutic Targets in Cardiovascular Diseases (Mar 2022)
    • Immunometabolism (Jan 2022)
    • Circadian Rhythm (Oct 2021)
    • Gut-Brain Axis (Jul 2021)
    • Tumor Microenvironment (Mar 2021)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Commentaries
    • Concise Communication
    • Editorials
    • Viewpoint
    • Top read articles
  • Clinical Medicine
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Author's Takes
  • In-Press Preview
  • Commentaries
  • Concise Communication
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
The Staphylococcus aureus Map protein is an immunomodulator that interferes with T cell–mediated responses
Lawrence Y. Lee, … , Damien McDevitt, Eric L. Brown
Lawrence Y. Lee, … , Damien McDevitt, Eric L. Brown
Published November 15, 2002
Citation Information: J Clin Invest. 2002;110(10):1461-1471. https://doi.org/10.1172/JCI16318.
View: Text | PDF
Article Infectious disease

The Staphylococcus aureus Map protein is an immunomodulator that interferes with T cell–mediated responses

  • Text
  • PDF
Abstract

Research Article

Authors

Lawrence Y. Lee, Yuko J. Miyamoto, Bradley W. McIntyre, Magnus Höök, Kirk W. McCrea, Damien McDevitt, Eric L. Brown

×

Figure 1

Options: View larger image (or click on image) Download as PowerPoint
Mean weight loss from Map–SA- and Map+SA-infected mice. Mice were intrav...
Mean weight loss from Map–SA- and Map+SA-infected mice. Mice were intravenously infected with either 107 Map–SA or Map+SA. Weights were taken before infection and every 7 days after infection for 4 weeks. Data are expressed as the mean ± SE of the mean of 26 and 24 mice/group for Map–SA– and Map+SA–infected mice, respectively. *P < 0.05, Student t test.

Copyright © 2022 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts